Manufactures vaccines for diseases like hepatitis, influenza, rubella and typhoid fever

The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.

Part of Zoetis, Inc., Zoetis Services LLC is a company headquartered in Florham Park, NJ, that discovers, develops, manufactures and sells animal health medicines and vaccines.

Part of GeoVax Labs, Inc., GeoVax, Inc. is a company headquartered in Smyrna, GA. The firm develops biotechnology and vaccines. It was founded in 2001 by Harriet Latham Robinson. GeoVax, Inc. was acquired by Dauphin Technology, Inc. on October 03, 2006.\nThe company says this about itself: GeoVax Labs, Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its MVA-VLP vaccine platform. GeoVax was the winner of the 2018 ��Best Biotech�� Vaccine Industry Excellence Awards, a finalist for the 2018 ��Best Prophylactic Vaccine�� Award for its Zika vaccine at the World Vaccine Congress, as well as a finalist for Pipelines of Promise at Buzz of Bio 2018. The Company��s development programs are focused on vaccines against HIV, Zika, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa) and malaria. GeoVax also is evaluating the use of its MVA-VLP platform in cancer immunotherapy, and for therapeutic use in chronic Hepatitis B infections. GeoVax��s vaccine platform supports in vivo production of non-infectious VLPs from the cells of the very person receiving the vaccine. The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection.

Becton, Dickinson & Co. engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Novartis Vaccines & Diagnostics, Inc. manufactures and markets health care and nutritional products. The company was founded in 1986 and is headquartered in East Hanover, NJ.

Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda holds an exclusive agreement with the Weizmann Institute to commercialize the unique intellectual property developed by the scientists. The income generated serves to support further basic research and science education. - Identify and assess research projects with commercial potential. - Protect the intellectual property of the Institute and its scientists. - Create business relationships and license the Institute’s inventions and technologies to the industry. - Channel funding from industry to research projects. For further information please contact Tamir Huberman, CIO and Head of Marketing

Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products. The company operates in two segments, Pharmaceuticals, and Nutritionals. The Nutritionals segment is operated through the company's subsidiary Mead Johnson Nutrition Company (Mead Johnson). The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business.

The Institute for Biomathematics and Biometry conducts fundamental research in areas including Epidemiology, Analysis of Complex Experimental Data, Analysis of Environmental Chemicals, Machine Learning, Bacterial Communication Processes in the Rhizosphere, the Regulation Pathway of NF-κB and Coagulation Cascades.

Sichuan Clover Biopharmaceuticals, Inc is a company headquartered in Chengdu, China, that develops and distributes biological therapies. It was founded in 2007 by Peng Liang. Joshua Liang has been the CEO of the firm since 2016.\nThe company says this about itself: Clover Biopharmaceuticals is a global, clinical-stage, research-based bio technology company focused on discovering, developing and commercializing transformative biologic therapies, with a focus on oncology and autoimmune diseases. Clover is utilizing its proprietary Trimer-Tag© technology platform to develop novel biologics targeting trimerization-dependent pathways. Additionally, Clover is leveraging its in-house cGMP biomanufacturing capabilities to develop select biosimilars.

Merial SAS develops, manufactures, and distributes pharmaceutical products and vaccines for animals. It provides therapeutic medicines that treat the diseases of dogs, cats, chickens, cows, pigs, and horses. The company was founded in 1997 and is headquartered in Treillieres, France.

Medigene Immunotherapies GmbH, part of MediGene AG, is a company headquartered in Planegg, Germany. The firm develops immunotherapy to treat cancer. It was founded in 2013 by Thomas Blankenstein and Dolores J. Schendel. Axel-Sven Malkomes is currently the CEO of the company. Medigene Immunotherapies GmbH was acquired by MediGene AG on January 27, 2014 for $13.05 million.\nThe company says this about itself: Based on more than 15 years of extensive research in the field of immunotherapy, Medigene Immunotherapies GmbH (formerly Trianta Immunotherapies GmbH) was founded late 2013 as a spin-off of the Helmholtz Zentrum München and was acquired by Medigene as a 100%subsidiary in January 2014. Medigene Immunotherapies pursues three complementary immunotherapeutic strategies to target various tumour types and stages: next generation antigen-tailored dendritic cell (DC)vaccines, T cell receptor (TCR)-based adoptive cell therapy and T cell-targeted antibodies (TABs). Each one is focused on T cells, a type of white blood cell that plays a pivotal role in immunity.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Chiron Corporation (/ˈkaɪrɒn/ KY-ron) was an American multinational biotechnology firm based in Emeryville, California that was acquired by Novartis on April 20, 2006. It had offices and facilities in eighteen countries on five continents. Chiron's business and research was in three main areas: biopharmaceuticals, vaccines, and blood testing. Chiron's vaccines and blood testing units were combined to form Novartis Vaccines and Diagnostics, while Chiron BioPharmaceuticals was integrated into Novartis Pharmaceuticals. In 2014, Novartis completed the sale of its blood transfusion diagnostics unit to Grifols and announced agreements for the sale of its vaccines unit to GlaxoSmithKline.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

B.G. Negev Technologies Ltd. serves as the link between industry and academic research programs. It products and technology transfer to existing companies. The company was founded in 1978 and is headquartered in Beer Sheva, Israel.